Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Next Previous
Trial Profile

A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma; Hodgkin's disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Takeda Oncology

    • Most Recent Events

    • 13 Dec 2022 Results using data from NCT01492088 and NCT02979522 to develop PPK models , identifying factors impacting the pharmacokinetics of ADC and MMAE, and exposure response analyses assessing the risk benefit profiles of brentuximab vedotin combined with chemotherapy, presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 28 Jun 2020 An population PK (POPPK) analysis used data from pediatric (NCT01492088) and adult (NCT00430846) studies of brentuximab vedotin to quantify body size effects on ADC exposure; results published in the Journal of Clinical Pharmacology
    • 26 Apr 2018 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top